(Q36397316)

English

Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

1 reference

Europe PubMed Central

Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1

object named as

Jens Gille

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2006

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Experimental Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

175-186

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

The microenvironment of the tumour-host interface

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Tumorigenesis and the angiogenic switch

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Development of the lymphatic vascular system: a mystery unravels

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Current clinical management of gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Intracellular signal transduction pathway proteins as targets for cancer therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Angiogenesis modulation in cancer research: novel clinical approaches

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Imaging of angiogenesis: from microscope to clinic

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Neoplastic Meningitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0625.2006.00400.X

21 January 2018

Identifiers

10.1111/J.1600-0625.2006.00400.X

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36397316&oldid=1777304493"